Published in Cardiovascular Business Week, February 5th, 2008
"We are very pleased with the progress of this collaboration investigating the therapeutic potential of niacin receptor agonists to treat atherosclerosis and other disorders. We are looking forward to the Phase 1 results and the continued progress of the program," said Jack Lief, Arena's President and Chief Executive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week